

## ESAX-HTN


### Esaxerenone v Eplerenone in the management of hypertension

DOI: 10.1161/HYPERTENSIONAHA.119.13569



More infographics @  
twitter.com/i/events/  
1057661851759230978

#### Background



Resistant hypertension causes heart disease

#### Current Management

Traditional antihypertensive meds


+

Spironolactone or **Eplerenone**

*Mineralocorticoid receptor (MR) antagonist*

Limited by mineralocorticoid side-effect profile (hyperkalemia)

#### Objective



Compare efficacy and safety of **esaxerenone** and **eplerenone**

*Esaxerenone: 4x more selective for MR than eplerenone*

#### Trial Design

N = 1001  
43 centers




SBP  $155.3 \pm 9.6$  mm Hg

DBP  $98.1 \pm 5.6$  mm Hg

Age  $55.5 \pm 9.6$  years

Male: 72.2%



12 weeks

#### Efficacy and Safety



$\Delta$  SBP

$\Delta$  DBP


Units: mm Hg




$K \geq 5.5$  or  $\geq 6$

Units mEq/L


#### Results: Efficacy



#### Results: Safety



#### Conclusions



#### The Future

- **Esaxerenone**  $\downarrow$  BP > **Eplerenone**
- **ESAX-DN**, **FIDELIO-DKD** (NCT02540993) and **FIGARO-DKD** (NCT02545049)  $\rightarrow$  New era of selective MR antagonism?

#### Learn More

NephTwitterArchive.com  
Search "fidelio" or "esax"  
of "figaro" to learn more